JP2015509972A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509972A5 JP2015509972A5 JP2014561514A JP2014561514A JP2015509972A5 JP 2015509972 A5 JP2015509972 A5 JP 2015509972A5 JP 2014561514 A JP2014561514 A JP 2014561514A JP 2014561514 A JP2014561514 A JP 2014561514A JP 2015509972 A5 JP2015509972 A5 JP 2015509972A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- metal salt
- lactose
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 239000011780 sodium chloride Substances 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 7
- 229910052751 metal Inorganic materials 0.000 claims 7
- 239000002184 metal Substances 0.000 claims 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 235000021355 Stearic acid Nutrition 0.000 claims 5
- 239000003381 stabilizer Substances 0.000 claims 5
- 239000008117 stearic acid Substances 0.000 claims 5
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 4
- 239000008101 lactose Substances 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000011859 microparticle Substances 0.000 claims 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 2
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims 2
- JYMKTJSCJHGOMJ-UHFFFAOYSA-N 5-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-2,3,4-triol Chemical group OCC1OC(O)C(O)C(O)C1OC1C(CO)C(O)C(O)C(O)O1 JYMKTJSCJHGOMJ-UHFFFAOYSA-N 0.000 claims 2
- MHQJUHSHQGQVTM-VHEBQXMUSA-M CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O MHQJUHSHQGQVTM-VHEBQXMUSA-M 0.000 claims 2
- 238000002144 chemical decomposition reaction Methods 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- -1 pyrimidin-1-yl Chemical group 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229940071138 stearyl fumarate Drugs 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000087 stabilizing Effects 0.000 claims 1
Claims (15)
- 有効成分としての微粒子の形態のその全部の立体異性体、互変異性体および同位元素誘導体ならびにその溶媒和物を包含する、6−(2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)−N,N−ビス(2−メトキシエチル)ヘキス−5−インアミド若しくはその製薬学的に許容できる塩である、式(I)の化合物
ステアリン酸マグネシウムのようなステアリン酸の金属塩およびフマル酸ステアリルの金属塩から選択される微粒子安定化剤の安定化量を前記製剤中に包含させることを含んでなる、
上記方法。 - 有効成分としての微粒子の形態のその全部の立体異性体、互変異性体および同位元素誘導体ならびにその溶媒和物を包含する、6−(2−((4−アミノ−3−(3−ヒドロキシフェニル)−1H−ピラゾロ[3,4−d]ピリミジン−1−イル)メチル)−3−(2−クロロベンジル)−4−オキソ−3,4−ジヒドロキナゾリン−5−イル)−N,N−ビス(2−メトキシエチル)ヘキス−5−インアミド若しくはその製薬学的に許容できる塩である、式(I)の化合物
- 式(I)の化合物がその遊離塩基の形態にある、請求項1に記載の方法。
- 式(I)の化合物が固体の結晶性の無水の形態にある、請求項3に記載の方法。
- 式(I)の化合物が、(±0.2)17.6、18.4、22.5および24.2°2θから選択される1、2、3若しくは4個のピークを含有するX線粉末回折パターンを有する固体の結晶の形態にある、請求項3に記載の方法。
- 安定化剤がステアリン酸の金属塩である、請求項1および3ないし5のいずれか1つに記載の方法。
- ステアリン酸の金属塩がステアリン酸マグネシウムである、請求項6に記載の方法。
- 有効成分が微粉化されている、請求項1および3ないし7のいずれか1つに記載の方法。
- 乳糖がα−乳糖一水和物である、請求項1および3ないし8のいずれか1つに記載の方法。
- 式(I)の化合物がその遊離塩基の形態にある、請求項2に記載の使用。
- 式(I)の化合物が固体の結晶性の無水の形態にある、請求項10に記載の使用。
- 式(I)の化合物が、(±0.2)17.6、18.4、22.5および24.2°2θから選択される1、2、3若しくは4個のピークを含有するX線粉末回折パターンを有する固体の結晶の形態にある、請求項10に記載の使用。
- 安定化剤がステアリン酸の金属塩である、請求項2および10ないし12のいずれか1つに記載の使用。
- 安定化剤がステアリン酸マグネシウムである、請求項13に記載の使用。
- 乳糖がα−乳糖一水和物である、請求項2および10ないし14に記載の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261610023P | 2012-03-13 | 2012-03-13 | |
US201261610012P | 2012-03-13 | 2012-03-13 | |
US61/610,012 | 2012-03-13 | ||
US61/610,023 | 2012-03-13 | ||
PCT/GB2013/050623 WO2013136075A1 (en) | 2012-03-13 | 2013-03-13 | Novel pharmaceutical formulations |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015509972A JP2015509972A (ja) | 2015-04-02 |
JP2015509972A5 true JP2015509972A5 (ja) | 2016-04-14 |
JP6189874B2 JP6189874B2 (ja) | 2017-08-30 |
Family
ID=49160309
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014561515A Pending JP2015509973A (ja) | 2012-03-13 | 2013-03-13 | 結晶性pi3キナーゼ阻害剤 |
JP2014561514A Expired - Fee Related JP6189874B2 (ja) | 2012-03-13 | 2013-03-13 | 新規製薬学的製剤 |
JP2017151378A Withdrawn JP2018008992A (ja) | 2012-03-13 | 2017-08-04 | 結晶性pi3キナーゼ阻害剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014561515A Pending JP2015509973A (ja) | 2012-03-13 | 2013-03-13 | 結晶性pi3キナーゼ阻害剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017151378A Withdrawn JP2018008992A (ja) | 2012-03-13 | 2017-08-04 | 結晶性pi3キナーゼ阻害剤 |
Country Status (36)
Country | Link |
---|---|
US (3) | US20150099768A1 (ja) |
EP (2) | EP2825202B1 (ja) |
JP (3) | JP2015509973A (ja) |
KR (2) | KR20140141596A (ja) |
CN (2) | CN104302650B (ja) |
AU (2) | AU2013234080B2 (ja) |
CA (2) | CA2864652A1 (ja) |
CL (2) | CL2014002385A1 (ja) |
CO (2) | CO7061079A2 (ja) |
CR (2) | CR20140416A (ja) |
CY (1) | CY1118565T1 (ja) |
DK (1) | DK2834244T3 (ja) |
EA (2) | EA025465B1 (ja) |
EC (2) | ECSP14018142A (ja) |
ES (2) | ES2650791T3 (ja) |
GT (2) | GT201400182A (ja) |
HK (2) | HK1203487A1 (ja) |
HR (1) | HRP20161383T1 (ja) |
HU (1) | HUE029420T2 (ja) |
IL (2) | IL233883A0 (ja) |
IN (2) | IN2014MN01998A (ja) |
LT (1) | LT2834244T (ja) |
MX (2) | MX357170B (ja) |
MY (1) | MY171125A (ja) |
NI (2) | NI201400101A (ja) |
NZ (2) | NZ628072A (ja) |
PE (2) | PE20142342A1 (ja) |
PH (2) | PH12014501713A1 (ja) |
PL (1) | PL2834244T3 (ja) |
PT (1) | PT2834244T (ja) |
SG (2) | SG11201404519UA (ja) |
SI (1) | SI2834244T1 (ja) |
TW (2) | TWI586378B (ja) |
UA (1) | UA115544C2 (ja) |
WO (2) | WO2013136076A1 (ja) |
ZA (2) | ZA201407374B (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
TWI586378B (zh) | 2012-03-13 | 2017-06-11 | 瑞斯比維特有限公司 | 新穎醫藥調配物 |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP6434416B2 (ja) | 2012-11-08 | 2018-12-05 | ライゼン・ファーマシューティカルズ・エスアー | PDE4阻害剤とPI3δ阻害剤または二重PI3δ−γキナーゼ阻害剤とを含有する薬学的組成物 |
TW201522341A (zh) | 2013-03-15 | 2015-06-16 | Respivert Ltd | 化合物 |
AR095353A1 (es) | 2013-03-15 | 2015-10-07 | Respivert Ltd | Compuesto |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2021012208A (es) | 2013-10-04 | 2023-01-19 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos. |
MX2016012021A (es) | 2014-03-19 | 2017-04-13 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. |
BR112017000132A2 (pt) | 2014-07-04 | 2018-01-09 | Lupin Ltd | composto, composição farmacêutica e método de tratamento ou prevenção de uma doença responsiva à inibição da atividade de pi3k |
EA201692456A1 (ru) * | 2014-07-09 | 2017-08-31 | Арвен Иладж Санайи Ве Тиджарет А.Ш. | Способ получения составов для ингаляции |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3350183A1 (en) | 2015-09-14 | 2018-07-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
AU2017251548B2 (en) * | 2016-04-15 | 2022-02-17 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Inhaled preparation of isoglycyrrhizic acid or salt thereof and use in preparing drugs for treating respiratory system diseases |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1204826B (it) | 1986-03-04 | 1989-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche per inalazione |
GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
WO1999028979A2 (en) | 1997-12-02 | 1999-06-10 | Alcatel Usa Sourcing, L.P. | Digital phone system |
US6645466B1 (en) * | 1998-11-13 | 2003-11-11 | Jago Research Ag | Dry powder for inhalation |
JP4876239B2 (ja) | 1999-01-11 | 2012-02-15 | プリンストン ユニバーシティー | 標的確認のための高親和性阻害剤およびその使用 |
DK1158958T3 (da) | 1999-03-05 | 2007-10-08 | Chiesi Farma Spa | Forbedret pulverformulering til inhalering |
PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
JP3649395B2 (ja) | 2000-04-27 | 2005-05-18 | 山之内製薬株式会社 | 縮合ヘテロアリール誘導体 |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
EP1578898A2 (en) | 2001-07-13 | 2005-09-28 | Virtual Drug Development, Inc. | Nad synthetase inhibitors and uses thereof |
AU2002317377A1 (en) | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
WO2004037176A2 (en) | 2002-10-21 | 2004-05-06 | Bristol-Myers Squibb Company | Quinazolinones and derivatives thereof as factor xa inhibitors |
TWI344955B (en) | 2003-03-14 | 2011-07-11 | Ono Pharmaceutical Co | Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient |
US7122557B2 (en) | 2003-03-18 | 2006-10-17 | Bristol-Myers Squibb Company | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors |
US20050002930A1 (en) | 2003-04-03 | 2005-01-06 | Johnson Dale E. | Methods of production and use of anti-integrin antibodies for the control of tissue granulation |
US7429596B2 (en) | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
JP2009513529A (ja) | 2003-07-11 | 2009-04-02 | グラクソ グループ リミテッド | ステアリン酸マグネシウムを含む医薬製剤 |
GB0316341D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Pharmaceutical formulations |
US20100267778A1 (en) | 2003-08-04 | 2010-10-21 | Shinya Kusuda | Diphenyl ether compound, process for producing the same, and use |
US20050054614A1 (en) | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
WO2005016348A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
GB0326632D0 (en) | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
US20050239809A1 (en) | 2004-01-08 | 2005-10-27 | Watts Stephanie W | Methods for treating and preventing hypertension and hypertension-related disorders |
CN101031569B (zh) * | 2004-05-13 | 2011-06-22 | 艾科斯有限公司 | 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮 |
CA2566436C (en) | 2004-05-13 | 2011-05-10 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
JP2008500338A (ja) | 2004-05-25 | 2008-01-10 | イコス・コーポレイション | 造血細胞の異常増殖を治療及び/又は予防する方法 |
CA2569406A1 (en) | 2004-06-04 | 2005-12-22 | Icos Corporation | Methods for treating mast cell disorders |
JP4894518B2 (ja) | 2004-09-13 | 2012-03-14 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
CA2598409A1 (en) | 2005-02-17 | 2006-08-24 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
GB0525254D0 (en) | 2005-12-12 | 2006-01-18 | Jagotec Ag | Powder compositions for inhalation |
MX2008012929A (es) | 2006-04-04 | 2008-12-17 | Univ California | Antagonistas de cinasa. |
CN101448505A (zh) | 2006-04-04 | 2009-06-03 | 加利福尼亚大学董事会 | Pi3激酶拮抗剂 |
CA2652886A1 (en) | 2006-05-24 | 2007-11-29 | Bayer Schering Pharma Aktiengesellschaft | High affinity human and humanized anti-.alpha.5.beta.1 integrin function blocking antibodies with reduced immunogenicity |
CA2655720A1 (en) | 2006-06-29 | 2008-01-10 | Schering Corporation | Substituted bicyclic and tricyclic thrombin receptor antagonists |
GB0622818D0 (en) | 2006-11-15 | 2006-12-27 | Jagotec Ag | Improvements in or relating to organic compounds |
US8362066B2 (en) | 2006-11-17 | 2013-01-29 | Treventis Corporation | Compounds and methods for treating protein folding disorders |
WO2008067219A2 (en) | 2006-11-29 | 2008-06-05 | Kalypsys, Inc. | Quinazolinone modulators of tgr5 |
WO2008104077A1 (en) | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
MX2009012066A (es) * | 2007-05-09 | 2009-11-19 | Novartis Ag | Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k. |
WO2008140750A1 (en) | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
SG187425A1 (en) | 2008-01-04 | 2013-02-28 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
US20110269779A1 (en) | 2008-11-18 | 2011-11-03 | Intellikine, Inc. | Methods and compositions for treatment of ophthalmic conditions |
US20110294803A1 (en) | 2008-12-04 | 2011-12-01 | Law Amanda J | Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders |
WO2010065932A1 (en) | 2008-12-05 | 2010-06-10 | Designmedix, Inc. | Modified chloroquines with single ring moiety or fused ring moiety |
US20110135655A1 (en) | 2009-01-13 | 2011-06-09 | PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication |
US8440677B2 (en) | 2009-03-24 | 2013-05-14 | Gilead Calistoga Llc | Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
AU2010281265A1 (en) | 2009-08-05 | 2012-03-22 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
GB0918249D0 (en) * | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
WO2011083387A1 (en) | 2010-01-07 | 2011-07-14 | Pfizer Limited | Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester |
CN201676365U (zh) | 2010-03-29 | 2010-12-22 | 山东京卫制药有限公司 | 带有语音提示的给药吸入装置 |
CN201692450U (zh) | 2010-06-22 | 2011-01-05 | 于清 | 用于药物输送的高效干粉吸入器 |
US20130157991A1 (en) | 2010-08-31 | 2013-06-20 | Osama Ahmed Aswania | Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same |
CA2813096C (en) | 2010-09-30 | 2019-10-29 | Chiesi Farmaceutici S.P.A. | Use of magnesium stearate in dry powder formulations for inhalation |
UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
CN202154919U (zh) | 2011-05-03 | 2012-03-07 | 王晓明 | 一种防交叉感染雾化吸入装置 |
TWI586378B (zh) | 2012-03-13 | 2017-06-11 | 瑞斯比維特有限公司 | 新穎醫藥調配物 |
-
2013
- 2013-03-13 TW TW102108766A patent/TWI586378B/zh not_active IP Right Cessation
- 2013-03-13 JP JP2014561515A patent/JP2015509973A/ja active Pending
- 2013-03-13 WO PCT/GB2013/050624 patent/WO2013136076A1/en active Application Filing
- 2013-03-13 CN CN201380013851.3A patent/CN104302650B/zh not_active Expired - Fee Related
- 2013-03-13 DK DK13711105.0T patent/DK2834244T3/en active
- 2013-03-13 EP EP13711104.3A patent/EP2825202B1/en active Active
- 2013-03-13 CA CA 2864652 patent/CA2864652A1/en not_active Abandoned
- 2013-03-13 ES ES13711104.3T patent/ES2650791T3/es active Active
- 2013-03-13 SG SG11201404519UA patent/SG11201404519UA/en unknown
- 2013-03-13 KR KR1020147026258A patent/KR20140141596A/ko not_active Application Discontinuation
- 2013-03-13 IN IN1998MUN2014 patent/IN2014MN01998A/en unknown
- 2013-03-13 EA EA201491674A patent/EA025465B1/ru not_active IP Right Cessation
- 2013-03-13 MX MX2014010990A patent/MX357170B/es active IP Right Grant
- 2013-03-13 PL PL13711105T patent/PL2834244T3/pl unknown
- 2013-03-13 CN CN201380013848.1A patent/CN104284679B/zh not_active Expired - Fee Related
- 2013-03-13 US US14/381,273 patent/US20150099768A1/en not_active Abandoned
- 2013-03-13 SG SG11201404522VA patent/SG11201404522VA/en unknown
- 2013-03-13 LT LTEP13711105.0T patent/LT2834244T/lt unknown
- 2013-03-13 SI SI201330362A patent/SI2834244T1/sl unknown
- 2013-03-13 WO PCT/GB2013/050623 patent/WO2013136075A1/en active Application Filing
- 2013-03-13 MX MX2014010991A patent/MX355299B/es active IP Right Grant
- 2013-03-13 EA EA201491675A patent/EA023715B1/ru not_active IP Right Cessation
- 2013-03-13 EP EP13711105.0A patent/EP2834244B1/en active Active
- 2013-03-13 MY MYPI2014702576A patent/MY171125A/en unknown
- 2013-03-13 JP JP2014561514A patent/JP6189874B2/ja not_active Expired - Fee Related
- 2013-03-13 UA UAA201408662A patent/UA115544C2/uk unknown
- 2013-03-13 PE PE2014001415A patent/PE20142342A1/es not_active Application Discontinuation
- 2013-03-13 HU HUE13711105A patent/HUE029420T2/en unknown
- 2013-03-13 IN IN2000MUN2014 patent/IN2014MN02000A/en unknown
- 2013-03-13 AU AU2013234080A patent/AU2013234080B2/en not_active Ceased
- 2013-03-13 NZ NZ628072A patent/NZ628072A/en not_active IP Right Cessation
- 2013-03-13 US US14/381,289 patent/US9642799B2/en not_active Expired - Fee Related
- 2013-03-13 TW TW102108767A patent/TWI617561B/zh not_active IP Right Cessation
- 2013-03-13 ES ES13711105.0T patent/ES2600705T3/es active Active
- 2013-03-13 NZ NZ627963A patent/NZ627963A/en not_active IP Right Cessation
- 2013-03-13 KR KR1020147026305A patent/KR20140131971A/ko not_active Application Discontinuation
- 2013-03-13 AU AU2013234081A patent/AU2013234081B2/en not_active Ceased
- 2013-03-13 PE PE2014001414A patent/PE20141964A1/es not_active Application Discontinuation
- 2013-03-13 PT PT137111050T patent/PT2834244T/pt unknown
- 2013-03-13 CA CA 2864643 patent/CA2864643A1/en not_active Abandoned
-
2014
- 2014-07-30 PH PH12014501713A patent/PH12014501713A1/en unknown
- 2014-07-30 IL IL233883A patent/IL233883A0/en unknown
- 2014-07-30 IL IL233886A patent/IL233886A/en not_active IP Right Cessation
- 2014-08-27 PH PH12014501922A patent/PH12014501922A1/en unknown
- 2014-08-29 CO CO14190112A patent/CO7061079A2/es unknown
- 2014-08-29 CO CO14190111A patent/CO7051030A2/es unknown
- 2014-09-01 GT GT201400182A patent/GT201400182A/es unknown
- 2014-09-02 GT GT201400183A patent/GT201400183A/es unknown
- 2014-09-05 NI NI201400101A patent/NI201400101A/es unknown
- 2014-09-05 NI NI201400100A patent/NI201400100A/es unknown
- 2014-09-09 CL CL2014002385A patent/CL2014002385A1/es unknown
- 2014-09-09 CL CL2014002386A patent/CL2014002386A1/es unknown
- 2014-09-10 CR CR20140416A patent/CR20140416A/es unknown
- 2014-09-10 CR CR20140417A patent/CR20140417A/es unknown
- 2014-09-10 EC ECIEPI201418142A patent/ECSP14018142A/es unknown
- 2014-09-12 EC ECIEPI201418630A patent/ECSP14018630A/es unknown
- 2014-10-10 ZA ZA2014/07374A patent/ZA201407374B/en unknown
- 2014-10-10 ZA ZA2014/07373A patent/ZA201407373B/en unknown
-
2015
- 2015-04-21 HK HK15103831.0A patent/HK1203487A1/zh not_active IP Right Cessation
- 2015-04-22 HK HK15103878.4A patent/HK1203812A1/xx not_active IP Right Cessation
-
2016
- 2016-10-25 HR HRP20161383TT patent/HRP20161383T1/hr unknown
- 2016-11-09 CY CY20161101148T patent/CY1118565T1/el unknown
-
2017
- 2017-05-08 US US15/588,845 patent/US20170239256A1/en not_active Abandoned
- 2017-08-04 JP JP2017151378A patent/JP2018008992A/ja not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015509972A5 (ja) | ||
JP2015509973A5 (ja) | ||
HRP20161383T1 (hr) | Kristalni inhibitori pi3 kinaze | |
AU2020203497B2 (en) | Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide | |
HRP20210928T1 (hr) | Soli ili ko-kristali 3- (3-dimetilamino-1-etil-2-metil-propil)-fenola | |
JP2018035160A5 (ja) | ||
JP2018534348A5 (ja) | ||
JP2012041365A5 (ja) | ||
JP2017504635A5 (ja) | ||
JP2014532638A5 (ja) | ||
JP2016534063A5 (ja) | ||
RU2016123828A (ru) | Комбинированная композиция для перорального введения, содержащая эзетимиб и розувастатин | |
BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
CZ2016276A3 (cs) | Pevné formy volné báze ibrutinibu | |
RU2016106336A (ru) | Противотуберкулезная композиция, содержащая рифампицин, изониазид, этамбутол и пиразинамид, и способ ее получения | |
JP2018530617A5 (ja) | ||
JP2009040767A5 (ja) | ||
JP6243265B2 (ja) | ロスバスタチン含有医薬製剤 | |
NO20070952L (no) | Formuleringer av suberoylanilidhydroksaminsyre og fremgangsmate for fremstilling av slike | |
JP2015534567A5 (ja) | ||
MY144613A (en) | Formulations of suberoylanilide hydroxamic acid and methods for producing same | |
JP2011500819A5 (ja) | ||
JP2020510061A5 (ja) | ||
JP2020500168A5 (ja) | ||
HRP20161691T1 (hr) | Derivati ariletinila |